{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:40:54Z","timestamp":1784644854133,"version":"3.55.0"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,9,18]]},"abstract":"<jats:p>Posterior reversible encephalopathy syndrome (PRES), first introduced in 1996, is a neurotoxic state characterised by seizures, headache, vision change, paresis, nausea and altered mental status. Risk factors include hypertension, eclampsia\/pre-eclampsia, infection\/sepsis and cancer chemotherapy. Although exposure to toxic agents is a common occurrence in patients who develop PRES, oxaliplatin has rarely been associated with it, with only 10 cases reported worldwide. We present the case of an oxaliplatin-induced PRES in a 23-year-old male patient who was started on oxaliplatin\/capecitabine as adjuvant chemotherapy for anal canal adenocarcinoma. The patient developed symptoms of headache, slurred speech and left-sided facial weakness on the ninth day after the first dose of oxaliplatin that lasted for 6\u20138\u2009hours. The patient experienced another episode next day with similar symptoms that lasted for 8\u2009hours. Oxaliplatin was withheld and the patient was discharged on capecitabine only. The patient had no new episodes since discharge on follow-up.<\/jats:p>","DOI":"10.1136\/bcr-2017-221571","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T07:25:50Z","timestamp":1507101950000},"page":"bcr-2017-221571","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES)"],"prefix":"10.1136","volume":"2017","author":[{"given":"Taimoor Khalid","family":"Janjua","sequence":"first","affiliation":[{"name":"Department of Oncology, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Post Graduate Medical Centre, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira Khan","family":"Afridi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila Anjum","family":"Zahid","sequence":"additional","affiliation":[{"name":"Department of Oncology, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340803"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.2","first-page":"205-10","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"65","author":"Lee","year":"2008","journal-title":"Arch Neurol"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00111-8"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.4","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0928"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.5","doi-asserted-by":"crossref","unstructured":"Legriel S , Pico F , Azoulay E . Understanding posterior reversible encephalopathy syndrome. InAnnual update in intensive care and emergency medicine 2011:631\u201353.","DOI":"10.1007\/978-3-642-18081-1_56"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.6","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0590"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.autrev.2015.05.006","article-title":"Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches","volume":"14","author":"Granata","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.8","first-page":"825","article-title":"Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging","volume":"26","author":"Brubaker","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.06.003"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.10","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/25273221"},{"issue":"2 Pt 2","key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.11","article-title":"Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy","volume":"6","author":"Tamaki","year":"1984","journal-title":"Hypertension"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.12","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0929"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.13","first-page":"386","article-title":"A case of oxaliplatin-related posterior reversible encephalopathy syndrome","volume":"6","author":"Skelton","year":"2007","journal-title":"Clin Colorectal Cancer"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5954"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.15","first-page":"1163","article-title":"A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)","volume":"36","author":"Nagata","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.16","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.026"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-011-9279-8"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1743-7563.2012.01544.x","article-title":"Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review","volume":"8","author":"Femia","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.19","first-page":"1","article-title":"Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy","volume":"2013","author":"Porcello Marrone","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.20","first-page":"1","article-title":"Oxaliplatin-Induced Tonic-Clonic Seizures","volume":"2015","author":"Rahal","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4103\/0973-1482.146134","article-title":"Oxaliplatin-induced posterior reversible encephalopathy syndrome with isolated involvement of pons","volume":"11","author":"Tang","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.189647"},{"key":"2025082801501966000_2017.oct03_1.bcr-2017-221571.23","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0549"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:50:30Z","timestamp":1756371030000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":23,"alternative-id":["10.1136\/bcr-2017-221571"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221571","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]}}}